BMXMF 106.75 bioMérieux S.A.
| Range: | 90.228-122.524 | Vol Avg: | 110 | Last Div: | 0.91 | Changes: | -0.64 |
| Beta: | 0.19 | Cap: | 13.31B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Thu Sep 21 2017 | Empoloyees: | 13409 | ||
| CUSIP: | CIK: | ISIN: | FR0013280286 | Country: | FR | ||
| CEO: | Mr. Pierre Boulud | Website: | https://www.biomerieux.com | ||||
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Stock Details
Positive 0.68
bioMérieux S.A. (BMXMF) Q2 2024 Earnings Call Transcript
bioMérieux S.A. (OTCPK:BMXMF) Q2 2024 Results Conference Call September 5, 2024 8:00 AM ET...
seekingalpha.com·Mon Sep 09 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow